Creditors of Valeant Pharmaceuticals are beginning to demand new terms that could further pressure the drugmaker’s business model, sources said.
Creditors of Valeant Pharmaceuticals are beginning to demand new terms that could further pressure the drugmaker’s business model, sources said.